Abstract
Background: Hepatocellular carcinoma (HCC) ranks as the fifth most common cancer globally and the third leading cause of cancer-related deaths. Systemic therapies such as lenvatinib or the combination of atezolizumab and bevacizumab have recently emerged as first-line therapies for advanced HCC. The introduction of tremelimumab with durvalumab (STRIDE regimen) has shown potential in improving overall survival (OS) in unresectable cases, making these patients candidates for surgical intervention post-treatment. Methods: The STRIDE-X study is a prospective, multicenter, single-arm trial aimed at evaluating the efficacy of single-dose tremelimumab combined with durvalumab, followed by hepatectomy, in patients with initially unresectable HCC. This non-randomized, open-label study will enroll subjects based on specific inclusion criteria. Eligible patients will undergo initial intravenous doses of tremelimumab and durvalumab, followed by an assessment of resectability via imaging at 8 and 16 weeks. If tumors become resectable, surgery will be scheduled 3–8 weeks after the last treatment dose. The primary endpoint is the incidence of postoperative complications of Clavien–Dindo grade III or higher following hepatectomy performed after STRIDE therapy. Secondary endpoints include resection rate, on-protocol resection rate, curative resection rate, post-hepatectomy liver failure, progression-free survival (PFS), OS, overall response rate, and ICG retention rate following STRIDE therapy. Safety and quality of life during the treatment course will also be assessed. Exploratory endpoints include analyses of plasma PD-L1, PD-1, CTLA-4, cytokines, circulating tumor DNA, and the immunological evaluation of resected surgical specimens. Discussion: This study aims to elucidate the safety of conversion surgery with the STRIDE regimen for initially unresectable HCC. In addition, efficacy (PFS and OS), the conversion rate during the treatment course, and analyses of relevant biomarkers will also be assessed.

This publication has 12 references indexed in Scilit: